BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. Chairman and CEO Oguzhan Atay exercised options for 3,183 Class A common shares on October 14, 2026, and 5,150 shares on October 15, at $2.8000 per share. He also reported multiple share sales on both dates, including 3,083 shares sold on October 14 at a weighted average price of $98.3198 per share. His spouse separately sold 2,667 shares at $98.0000 per share that day, with a reported resulting holding of 149,168 shares. Atay’s transactions were made under a Rule 10b5-1 trading plan adopted June 5, 2026; his spouse’s sale was under a separate plan adopted June 7, 2026.
BillionToOne, Inc. (BLLN) officer and director Oguzhan Atay reported a proposed sale of 5,150 Class A shares, listed at an aggregate market value of $516,188.60, with an approximate sale date of October 15, 2026. The notice lists a cash-paid stock-option exercise of 5,150 Class A shares dated October 15, 2026. It also identifies prior three-month sales by Atay, his spouse Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust; Icontrust LLC is identified as trustee for the trust account.
BillionToOne, Inc. (BLLN) Chairman and CEO Oguzhan Atay exercised 16,667 options at $2.80 per share on October 12, 2026, acquiring 16,667 Class A shares. The options were fully vested and exercisable.
The transactions reported sales of 19,334 Class A shares, including five direct sale transactions and 2,667 shares sold by Atay’s spouse. The direct sale rows reported weighted-average prices from $91.5712 to $96.3924 per share; the spouse’s sale had a $97.6100 weighted-average price. Atay’s transactions were under a Rule 10b5-1 plan adopted June 5, 2026; his spouse’s sale was under a separate plan adopted June 7, 2026. The spouse-held position following the sale was reported as 151,835 shares.
BillionToOne, Inc. (BLLN) lists officer and director Oguzhan Atay’s proposed sale of 3,183 Class A shares, with an aggregate market value of $313,019.82 and an approximate sale date of October 14, 2026; Fidelity Brokerage Services LLC is the listed broker. The notice also identifies a 3,183-share Class A stock option exercise from the issuer for cash on October 14, 2026. Sales during the prior three months are listed for Oguzhan Atay, his spouse Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust; remarks identify Icontrust LLC as trustee for the trust account.
BillionToOne, Inc. (BLLN) is identified as the issuer in a Rule 144 notice for a proposed sale of 2,667 Class A shares for the account of Ezgi N. Akcinar Atay, spouse of Oguzhan Atay, an Officer and Director. The notice lists an aggregate market value of $261,366.00, Fidelity Brokerage Services LLC as broker, and October 14, 2026 as the approximate sale date on NASDAQ.
BillionToOne, Inc. reported that its General Counsel, Chief Compliance Officer and Secretary, Thomas P. Lynch, exercised 8,000 stock options at an exercise price of $8.65 per share on October 8, 2026, acquiring 8,000 Class A Common Stock shares. After the transactions, he reported options covering 40,974 shares and direct holdings of 8,700 Class A shares.
BillionToOne, Inc. reported a proposed sale of 2,667 Class A shares with an aggregate market value of $260,325.87 through Fidelity Brokerage Services LLC; October 12, 2026, is listed as the approximate sale date. The notice names Oguzhan Atay as the person for whose account the securities are to be sold, but states that the sale occurred in the account of his spouse, Ezgi N. Akcinar Atay. It identifies Oguzhan Atay as an officer and director.
BillionToOne, Inc. (BLLN) is the issuer named in Oguzhan Atay’s notice of a proposed sale of 16,667 Class A shares, with an aggregate market value of $1,563,124.60 and an approximate sale date of October 12, 2026. The shares were acquired from the issuer through a stock option exercise on October 12, 2026, with cash payment. The notice also lists sales during the prior three months in accounts of Oguzhan Atay, his spouse Ezgi N. Akcinar Atay, and the Atay 2021 Dynasty Trust; Icontrust LLC made the trust sales as trustee.
At BillionToOne, Inc. (BLLN), SVP of Laboratory Operations John Roderick ten Bosch reported two sales of 1,417 Class A common shares each on October 5, 2026, at $105.15 per share. Both transactions were made under a Rule 10b5-1 trading plan adopted on June 2, 2026.
BillionToOne, Inc. (BLLN) Chief Technology Officer David Tsao exercised options to acquire 20,000 shares of Class A common stock at $2.80 per share on October 5, 2026. He sold 20,000 shares that day in 11 transactions. The common-stock acquisitions and sales were reported under a Rule 10b5-1 trading plan adopted June 5, 2026. The options were fully vested and exercisable and expire June 7, 2031.